miR-129-2 mediates down-regulation of progesterone receptor in response to progesterone in breast cancer cells.

Mukul GodbolePratik ChandraniNilesh GardiHemant DhamneKuldeep PatelNeelima YadavSudeep GuptaRajendra BadweAmit Dutt

Published in: Cancer biology & therapy (2017)

miR-129-2 mediates down-regulation of PR in breast cancer cells in response to progesterone, while anti-miR-129-2 could potentiate PR expression levels among patients with inadequate PR levels. Thus, modulation of activity of miR-129-2 could stabilize PR expression and potentially improve response to hormonal therapy under adjuvant or neo-adjuvant settings.

Keyphrases

long non coding rna
cell proliferation
poor prognosis
breast cancer cells
long noncoding rna
early stage
estrogen receptor
binding protein
type diabetes
stem cells
mesenchymal stem cells
polycystic ovary syndrome
smoking cessation